Early-Stage Triple-Negative Breast Cancer
Panelists discuss how triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by the absence of 3 key receptors: estrogen receptor, progesterone receptor, and HER2 protein. TNBC tends to grow and spread faster than other breast cancer types, presenting unique treatment challenges since common targeted therapies like hormone therapy and HER2-targeted treatments are ineffective. Standard treatment primarily relies on chemotherapy, surgery, and radiation.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue
February 13th 2024The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.
